CAJ | 학술논문

目的：探讨细胞角蛋白19（cytokeratin 19，CK-19）检测对乳腺癌患者新辅助化疗疗效评估的价值。方法采用实时定量逆转录聚合酶链反应（ qRT-PCR ）技术检测114例乳腺癌患者新辅助化疗前后外周血CK-19 mRNA表达水平的变化。结果化疗前乳腺癌患者的CK-19 mRNA阳性率为36．8％（42/114），与患者的年龄、肿瘤大小，TNM分期、绝经状态、雌激素受体（ER）及孕激素受体（PR）的表达无关（P＞0．05），而与腋窝淋巴结转移及临床分期有关（P＜0．01）。化疗后CK-19 mRNA表达水平较化疗前明显降低（P＜0．01）。结论CK-19可以作为乳腺癌患者新辅助化疗疗效的评价指标之一。
목적：탐토세포각단백19（cytokeratin 19，CK-19）검측대유선암환자신보조화료료효평고적개치。방법채용실시정량역전록취합매련반응（ qRT-PCR ）기술검측114례유선암환자신보조화료전후외주혈CK-19 mRNA표체수평적변화。결과화료전유선암환자적CK-19 mRNA양성솔위36．8％（42/114），여환자적년령、종류대소，TNM분기、절경상태、자격소수체（ER）급잉격소수체（PR）적표체무관（P＞0．05），이여액와림파결전이급림상분기유관（P＜0．01）。화료후CK-19 mRNA표체수평교화료전명현강저（P＜0．01）。결론CK-19가이작위유선암환자신보조화료료효적평개지표지일。
Objective To explore the value of cytokeratin 19 ( CK-19 ) for evaluating the efficacy of neoadjuvant chemotherapy for breast cancer .Methods The CK-19 mRNA expression in the blood of 114 breast cancer patients was detected before and after neoadjuvant chemotherapy by real -time quantitative RT-PCR ( qRT-PCR) .Results The positive rate of CK-19 mRNA in breast cancer patients before treatment was 36.8%(42/114), and the patient′s age, tumor size, TNM staging, menopausal status , the expression of estrogen receptor ( ER) , and progesterone receptor ( PR) were not associated with the expression level of CK -19 mRNA,but the expression level of CK -19 mRNA showed strong correlation with axillary lymph node metastasis and clinical stage .After chemotherapy ,the expression level of CK -19 mRNA was significanly lower than that before chemotherapy .Conclusion CK-19 can be used as one of the early indi-cators of efficacy in neoadjuvant chemotherapy for breast cancer patients .